TP53 and neuroblastoma: Using a multiplexed screening system of 748 cell lines, we again found that the degree to which PPM1D inhibition with GSK280371 sensitized cells to daunorubicin was also TP53-dependent and confirmed these results in 2 distinct cellular contexts, Ewing sarcoma and neuroblastoma.